EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieBeobachtungsstudieOpen Access · CC BY 4.0

The Coronary Access After TAVI (CAvEAT) Study

Giuseppe Tarantini, Luca Nai Fovino, Flavia Belloni, Marco Barbierato, Francesco Gallo, Matteo Vercellino, Carlo Trani, Francesco Burzotta, Lluis Asmarats Serra, Anna Sonia Petronio, Francesco Bedogni, Sergio Berti und 20 weitere

JACC: Cardiovascular Interventions · 2025-06 · 18 (12) · 1571-1583

DOI: 10.1016/j.jcin.2025.05.002 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2025-06. Verfasst von Giuseppe Tarantini und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. Electronic address: giuseppe.tarantini.1@gma…. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Aortic Valve, Aortic Valve Stenosis, Coronary Angiography. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: As transcatheter aortic valve replacement (TAVR) is now performed in patients with longer life expectancy, the need for coronary access (CA) after TAVR is expected to rise. OBJECTIVES: The aim of this study was to evaluate the feasibility of CA after TAVR with 4 different types of transcatheter heart valves (THVs). METHODS: In the multicenter, prospective CAvEAT (Coronary Access After TAVI; NCT04647864) registry, coronary angiography was performed immediately following transfemoral TAVR using short-frame SAPIEN 3 or SAPIEN 3 Ultra (SAPIEN 3/Ultra) and tall-frame ACURATE neo or ACURATE neo2 (ACURATE neo/neo2), Portico or Navitor, and Evolut Pro or Evolut Pro+ (Evolut Pro/Pro+) THVs. The primary endpoint was defined as selective CA of both coronary arteries. RESULTS: In total, 632 patients were enrolled (mean age 82 years, 59% women). Selective CA of both coronary arteries was achieved in 89% of SAPIEN 3/Ultra, 63% of ACURATE neo/neo2, 62% of Portico or Navitor, and 45% of Evolut Pro/Pro+ THVs (P < 0.001). Unfeasible CA of at least 1 coronary artery occurred in 2%, 6%, 6%, and 9% of cases, respectively (P = 0.06). In pairwise comparisons, the incidence of the primary endpoint was significantly higher for the SAPIEN 3/Ultra compared with all tall-frame THVs (P < 0.001). Among tall-frame devices, no significant difference was observed between the ACURATE neo/neo2 and the Portico or Navitor (P = 0.9), but both devices demonstrated higher rates of the primary endpoint than the Evolut Pro/Pro+ (P = 0.005 and P = 0.002, respectively). Multivariate analysis identified implantation depth, moderate or severe commissural misalignment, and use of a tall-frame THV as independent predictors of unfeasible or nonselective CA. CONCLUSIONS: The short-frame SAPIEN 3/Ultra THV demonstrated the highest rate of selective CA following TAVR. Among tall-frame THVs, the large-cell designs of the Portico or Navitor and ACURATE neo/neo2 outperformed the closed-cell Evolut Pro/Pro+ in terms of selective CA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcatheter Aortic Valve ReplacementAortic ValveAortic Valve StenosisCoronary AngiographyCardiac CatheterizationCoronary VesselsHumansFemaleRegistriesMaleProspective StudiesAged, 80 and overAgedTreatment OutcomeHeart Valve ProsthesisFeasibility StudiesProsthesis DesignRisk FactorsTime FactorsPunctures

Stichwörter der Autor:innen

aortic stenosiscoronary accesscoronary artery diseasetranscatheter aortic valve replacement

Autor:innen und Institutionen

  • Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. Electronic address: giuseppe.tarantini.1@gmail.com.
  • Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
  • S. Spirito Hospital, Rome, Italy.
  • Department of Cardiology, Ospedale dell'Angelo, AULSS3 Serenissima, Mestre, Venice, Italy.
  • Department of Cardiovascular Sciences, Ospedale San Martino, Genoa, Italy.
  • Fondazione Policlinico A. Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy.

Zitieren

APA

Tarantini, G., Nai Fovino, L., Belloni, F., Barbierato, M., Gallo, F., Vercellino, M., Trani, C., Burzotta, F., Asmarats Serra, L., Petronio, A. S., Bedogni, F., Berti, S., Bertolini, A., Fabris, T., Tito, A., Musto, C., Giordano, A., Corcione, N., Maisano, F., …, & CAvEAT Investigators and the Italian Society of Interventional Cardiology (2025). The Coronary Access After TAVI (CAvEAT) Study. JACC: Cardiovascular Interventions, 18(12), 1571-1583. https://doi.org/10.1016/j.jcin.2025.05.002

Vancouver

Tarantini G, Nai Fovino L, Belloni F, Barbierato M, Gallo F, Vercellino M, et al. The Coronary Access After TAVI (CAvEAT) Study. JACC: Cardiovascular Interventions. 2025;18(12):1571-1583. doi:10.1016/j.jcin.2025.05.002

BibTeX
@article{Tarantini2025,
  author = {Tarantini, Giuseppe and Nai Fovino, Luca and Belloni, Flavia and Barbierato, Marco and Gallo, Francesco and Vercellino, Matteo and Trani, Carlo and Burzotta, Francesco and Asmarats Serra, Lluis and Petronio, Anna Sonia and Bedogni, Francesco and Berti, Sergio and Bertolini, Andrea and Fabris, Tommaso and Tito, Antonio and Musto, Carmine and Giordano, Arturo and Corcione, Nicola and Maisano, Francesco and Medda, Massimo and Loi, Bruno and Cernetti, Carlo and Favero, Luca and Di Lorenzo, Emilio and Gregori, Dario and Lorenzoni, Giulia and Orzalkiewicz, Mateusz and Esposito, Giovanni and Saia, Francesco and Cardaioli, Francesco and Marchese, Alfredo and CAvEAT Investigators and the Italian Society of Interventional Cardiology, CAvEAT Investigators and the Italian Society of Interventional Cardiology},
  title = {The Coronary Access After TAVI (CAvEAT) Study},
  journal = {JACC: Cardiovascular Interventions},
  year = {2025},
  volume = {18},
  number = {12},
  pages = {1571--1583},
  doi = {10.1016/j.jcin.2025.05.002}
}
Kostenlos starten →